The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 13, 2022

Filed:

Aug. 10, 2020
Applicants:

Leading Biosciences, Inc., Carlsbad, CA (US);

The Regents of the University of California, Oakland, CA (US);

Inventors:

Geert W. Schmid-Schonbein, Del Mar, CA (US);

Yung-Tsai (Andrew) Lee, Taipei, TW;

Jeng Wei, Taipei, TW;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/195 (2006.01); A61K 31/765 (2006.01); A61K 31/185 (2006.01); A61K 31/19 (2006.01); A61K 31/24 (2006.01); A61K 38/57 (2006.01); A61K 9/00 (2006.01); A61K 31/10 (2006.01); A61K 31/145 (2006.01); A61K 31/155 (2006.01); A61K 31/216 (2006.01); A61K 31/661 (2006.01); A61K 38/17 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 9/08 (2006.01);
U.S. Cl.
CPC ...
A61K 31/195 (2013.01); A61K 9/0053 (2013.01); A61K 31/10 (2013.01); A61K 31/145 (2013.01); A61K 31/155 (2013.01); A61K 31/185 (2013.01); A61K 31/19 (2013.01); A61K 31/216 (2013.01); A61K 31/24 (2013.01); A61K 31/661 (2013.01); A61K 31/765 (2013.01); A61K 38/1722 (2013.01); A61K 38/57 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 9/08 (2013.01);
Abstract

The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.


Find Patent Forward Citations

Loading…